Stiris Research Inc. Awarded 2 Global Rare Disease Studies
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it has been awarded two Global, Phase II Paroxysmal Nocturnal Hemoglobinuria (PNH) trials in collaboration with our European CRO partner.
“Stiris’ focus is working on clinical trials in areas of unmet needs and having the opportunity to work on these global rare disease trials is allowing us to play a critical role in the advancement of research and patient care,” Amanda Carrera, Vice President.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare a rare blood disorder in which causes red blood cells to break apart. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are created in the bone marrow and grow and eventually develop into red blood cells, white blood cells and platelets. Patients with PNH have defective red blood cells and are susceptible to premature destruction “hemolysis” caused by their immune system. The surface of a person’s blood cells is missing a protein that protects them from the body’s immune system. When the red blood cells hemolyze the hemoglobin inside is released and it is this release of hemoglobin that causes many of the PNH symptoms and can lead to life-threatening complications.
PNH can appear at any age and in any race or gender but is diagnosed most often in people in their 30s and 40s. Experts estimate between 400 and 500 cases are diagnosed in the U.S. each year and the prevalence is estimated to be between 0.5-1.5 million people in the general population (https://www.aamds.org/diseases) and (https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/).
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: